Cellebrite DI (NASDAQ:CLBT) Research Coverage Started at Lake Street Capital

Lake Street Capital started coverage on shares of Cellebrite DI (NASDAQ:CLBT) in a report released on Friday, Benzinga reports. The brokerage issued a buy rating and a $13.00 target price on the stock.

Other equities analysts have also recently issued reports about the stock. Needham & Company LLC upped their target price on shares of Cellebrite DI from $13.00 to $13.50 and gave the company a buy rating in a research note on Thursday, March 28th. William Blair upgraded shares of Cellebrite DI from a market perform rating to an outperform rating in a research note on Wednesday, March 13th. Bank of America upped their target price on shares of Cellebrite DI from $12.00 to $13.00 and gave the company a buy rating in a research note on Monday, April 1st. Finally, Craig Hallum upped their target price on shares of Cellebrite DI from $14.00 to $16.00 and gave the company a buy rating in a research note on Monday, April 1st. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of Buy and a consensus price target of $12.42.

Cellebrite DI Stock Performance

Shares of CLBT opened at $10.47 on Friday. The company’s 50 day moving average price is $11.25 and its 200 day moving average price is $9.23. Cellebrite DI has a 52 week low of $5.22 and a 52 week high of $12.50. The company has a market capitalization of $2.15 billion, a PE ratio of -24.35, a PEG ratio of 1.84 and a beta of 1.53.

Cellebrite DI (NASDAQ:CLBT) last posted its earnings results on Thursday, February 15th. The company reported $0.08 EPS for the quarter, topping the consensus estimate of $0.06 by $0.02. The company had revenue of $93.01 million during the quarter, compared to the consensus estimate of $85.43 million. Cellebrite DI had a negative net margin of 24.94% and a positive return on equity of 173.14%. On average, equities analysts forecast that Cellebrite DI will post 0.32 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Kranot Hishtalmut Le Morim Ve Gananot Havera Menahelet LTD bought a new position in shares of Cellebrite DI in the 4th quarter valued at about $1,774,000. Voss Capital LLC boosted its stake in shares of Cellebrite DI by 207.7% in the 4th quarter. Voss Capital LLC now owns 1,835,000 shares of the company’s stock valued at $15,891,000 after purchasing an additional 1,238,580 shares during the last quarter. Brasada Capital Management LP boosted its stake in shares of Cellebrite DI by 125.1% in the 3rd quarter. Brasada Capital Management LP now owns 375,332 shares of the company’s stock valued at $2,762,000 after purchasing an additional 208,566 shares during the last quarter. Clal Insurance Enterprises Holdings Ltd acquired a new stake in shares of Cellebrite DI in the 3rd quarter valued at approximately $50,270,000. Finally, Swiss National Bank raised its position in shares of Cellebrite DI by 30.7% in the 3rd quarter. Swiss National Bank now owns 107,800 shares of the company’s stock valued at $825,000 after acquiring an additional 25,300 shares during the period. Institutional investors own 45.88% of the company’s stock.

Cellebrite DI Company Profile

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.